NOTE: The following includes references to in the online news media. If you are interested in seeing the full article you will need to contact archives department of the source publication. We do not have copies of any articles described on this site.

Amgen (AMGN)

Amgen

Tips to help you to make a fresh start in 2005
[excerpt] Similarly, Kevin Sharer interviewed the top 100 executives at Amgen after he became CEO in 2000 - even though he'd already been company president for the prior ... [/excerpt]
On 28 Dec 2004 in Arizona Republic

Amgen Ends Promising Drug Trial
[excerpt] Amgen, the drug company that manufactures GDNF, announced the experiment Allen and Kaufman took part in was "inconclusive." Amgen also presented data showing ... [/excerpt]
On 28 Dec 2004 in 7Online.com

County businesses grow, diversify, adjust to the challenges
[excerpt] Kevin Sharer will guide the world's largest biotechnology company and the county's top private employer through a historic year. Amgen Inc. ... [/excerpt]
On 28 Dec 2004 in Ventura County Star (subscription)

Medication May Reduce Incidence, Severity Of Mouth Sores In Some ...
[excerpt] UNC Hospitals and UNC Lineberger represented one of the 13 study sites for the trial sponsored by Amgen Inc. The 212 cancer patients ... [/excerpt]
On 28 Dec 2004 in Science Daily (press release)

International Drug Approvals: Pegasys, Advate, Eligard, Mimpara
[excerpt] Cinacalcet HCl (Mimpara, known in the US as Sensipar, made by Amgen Inc.) was approved by the European Commission (EC) for use in the European Union (EU) in ... [/excerpt]
On 28 Dec 2004 in Medscape (subscription)

R&D Directions to Honor Top 10 Pipelines at Drug Development ...
[excerpt] Conference faculty will include senior representatives from Amgen, Inc.; AstraZeneca; Avalon Pharmaceuticals, Inc.; Catalyst Law Group, APC; Eli Lilly and ... [/excerpt]
On 28 Dec 2004 in PharmaLive.com (press release)

Spotting Biotech's 2005 Stars
[excerpt] ...large, profitable biotechs. But it's still less appreciated than its better-known peers Amgen (AMGN) and Genentech. Gilead trades ... [/excerpt]
On 28 Dec 2004 in Milwaukee Channel.com

Santa Ain't Done Yet
[excerpt] ...biotech sector. Genzyme (GENZ:Nasdaq - news - research) added 2.3% and Amgen (AMGN:Nasdaq - news - research) rose 1.6%. The really ... [/excerpt]
On 28 Dec 2004 in TheStreet.com

On the Newsstand: Year-end issues have mags marching to similar ...
[excerpt] ...other currencies, says Forbes. Its end-of-the-year issue also picks what it calls the company of the year - Amgen. Forbes says the ... [/excerpt]
On 28 Dec 2004 in Boston Herald

Amgen Gets FDA Approval for Kepivance
[excerpt] Biotechnology giant Amgen Inc. reported ... Amgen said the approval was based on late-stage clinical trial data submitted by the company. In ... [/excerpt]
On Dec 15, 2004 in Forbes

Amgen "overweight"
[excerpt] 20 (newratings.com) - In a research note published on December 17, analysts at Prudential Financial maintain their "overweight" rating on Amgen Inc (AMGN.NAS). ... [/excerpt]
On Dec 20, 2004 in New Ratings

Amgen "outperform"
[excerpt] NEW YORK, December 13 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Amgen Inc (AMGN.NAS). ... [/excerpt]
On Dec 13, 2004 in New Ratings

Amgen wins approval for Kepivance
[excerpt] BOSTON (CBS.MW) -- Amgen said late Wednesday that the Food and Drug Administration approved its drug to treat a painful condition associated with high-dose ... [/excerpt]
On Dec 15, 2004 in Investor's Business Daily (subscription)

Amgen's Kepivance Approved For Mucositis In Blood Cancers
[excerpt] As expected, Amgen Inc. ... The Amgen drug is dosed three times before the conditioning regimen that precedes the transplant, and three times after the procedure. ... [/excerpt]
On Dec 16, 2004 in BioWorld Online (subscription)

Amgen cancer therapy drug gets approval
[excerpt] Amgen Inc., the world's largest biotechnology company, won US approval Wednesday for a drug to treat severe mouth sores in some chemotherapy patients. ... [/excerpt]
On Dec 16, 2004 in Ventura County Star (subscription)

Amgen "outperform"
[excerpt] NEW YORK, December 16 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Amgen Inc (AMGN.NAS). The target price is set to $82. ... [/excerpt]
On Dec 16, 2004 in New Ratings

Amgen CFO Nanula Elected to Boeing Board of Directors
[excerpt] PRNewswire-FirstCall/ -- The Boeing Company (NYSE: BA) today announced that Richard D. Nanula, executive vice president and chief financial officer, Amgen Inc. ... [/excerpt]
On Dec 13, 2004 in PR Newswire (press release)

AMGEN'S KEPIVANCE RECEIVES FDA APPROVAL FOR SEVERE ORAL MUCOSITIS
[excerpt] The Food and Drug Administration approved Amgen Inc.’s Kepivance (palifermin) for the treatment of oral mucositis. According to ... [/excerpt]
On Dec 16, 2004 in PharmExec.com

Amgen gets FDA nod for Kepivance
[excerpt] By Rachel Brand, Rocky Mountain News. Thousand Oaks, Calif.-based Amgen Inc. ... Amgen is conducting tests in hopes of wider product approval. ... [/excerpt]
On Dec 15, 2004 in Rocky Mountain News

Amgen Names Willard Dere Senior Vice President, Global Development
[excerpt] THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec 14, 2004 - Amgen Inc. ... In addition, Dere will also be named Amgen's chief medical officer. ... [/excerpt]
On Dec 14, 2004 in PharmaLive.com (press release)

Amgen: Healthy Outlook
[excerpt] Standard & Poor's just published its 2005 forecast issue of The Outlook, in which it names biotechnology company Amgen (AMGN) as one of ten stocks investors ... [/excerpt]
On Dec 20, 2004 in Kiplinger.com

Amgen's rating is upgraded to 'buy'
[excerpt] The rating of Amgen Inc. shares was raised Monday ... Matrix USA. Shares of Amgen (Nasdaq: AMGN) remained unchanged Monday at $63.95. The upgrade ... [/excerpt]
On Dec 14, 2004 in Ventura County Star (subscription)

Two Amgen Drugs Fast-Tracked
[excerpt] Two drugs being developed by Amgen (AMGN:Nasdaq - news - research), one for a blood disorder and one for tumors in the digestive tract, will receive expedited ... [/excerpt]
On Dec 7, 2004 in TheStreet.com

Amgen Seen Lacking 'Compelling Growth Drivers'
[excerpt] Credit Suisse First Boston maintained a "neutral" rating for Amgen (nasdaq: AMGN - news - people ) and said that while shares are reasonably valued it remains ... [/excerpt]
On Dec 6, 2004 in Forbes

Amgen Sets $5 Billion Buyback
[excerpt] Amgen (AMGN:Nasdaq - news - research) authorized the repurchase of $5 billion in common shares, building on a previous clearance that still has about $1 ... [/excerpt]
On Dec 7, 2004 in TheStreet.com

Amgen Board OKs $5 Billion Buyback
[excerpt] Biotechnology company Amgen Inc. on Tuesday said its board authorized additional repurchases of up to $5 billion of its common stock ... [/excerpt]
On Dec 7, 2004 in Forbes

Amgen: Neulasta Shown to Lower Infection
[excerpt] Biotech giant Amgen Inc. reported ... placebo. Shares of Amgen closed Friday down 38 cents, or 0.6 percent, to $63.95 on the Nasdaq. [/excerpt]
On Dec 10, 2004 in Forbes

FDA Grants Fast Track Designation for Amgen's AMG 531 and AMG 706 ...
[excerpt] THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec 6, 2004 - Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today ... [/excerpt]
On Dec 6, 2004 in PharmaLive.com (press release)

Nominations Open for the Amgen Award For Science Teaching ...
[excerpt] THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 29, 2004--Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today ... [/excerpt]
On Nov 29, 2004 in Business Wire (press release)

AMGEN GRANTED FAST TRACK STATUS FOR GIST, ITP DRUGS
[excerpt] Amgen Inc. received fast track designations from the Food and Drug Administration for AMG 531 and AMG 706. AMG 706 is currently ... [/excerpt]
On Dec 6, 2004 in PharmExec.com

Biotech, pharma rise; Amgen gains on $5bln buyback
[excerpt] By Val Brickates Kennedy. BOSTON (CBS.MW) -- The biotechnology and pharmaceutical sectors closed in positive territory on Wednesday, with shares of Amgen Inc. ... [/excerpt]
On Dec 8, 2004 in Investor's Business Daily (subscription)

Amgen Announces $5 Billion Stock Repurchase Plan
[excerpt] THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec 7, 2004 - Amgen Inc. ... This new authorization reflects Amgen's confidence in its long-term prospects. ... [/excerpt]
On Dec 8, 2004 in PharmaLive.com (press release)

Medarex to Receive Milestone Payment from Amgen; 21st UltiMAb(R) ...
[excerpt] ...(NASDAQ:MEDX) today announced that it will receive an undisclosed milestone payment from its licensing partner, Amgen Inc., for the advancement of an antibody ... [/excerpt]
On Nov 29, 2004 in mysan.de

Amgen drugs getting FDA fast track
[excerpt] By AP. Biotechnology company Amgen Inc. said the Food and Drug Administration granted a "fast-track" designation for two of its experimental ... [/excerpt]
On Dec 8, 2004 in Ventura County Star (subscription)

Amgen to buy back $5 billion shares
[excerpt] BOSTON (CBS.MW) - Biotechnology giant Amgen said late Tuesday that its board of directors has authorized the repurchase of up to $5 billion of its shares, a ... [/excerpt]
On Dec 7, 2004 in Investor's Business Daily (subscription)

Amgen to give science teachers awards
[excerpt] Amgen Inc. will ... tomorrow. The biotechnology giant is taking nominations for the 14th annual Amgen Award for Science Teaching Excellence. ... [/excerpt]
On Nov 30, 2004 in Ventura County Star (subscription)

Amgen board OKs additional buyback
[excerpt] Amgen Inc. ... Shares of Amgen (Nasdaq: AMGN) ended the regular trading down 91 cents, or 1.5 percent, at $61.95 Tuesday. National Technical Systems Inc. ... [/excerpt]
On Dec 8, 2004 in Ventura County Star (subscription)

Amgen Drug Boosts Blood Cells for Clotting
[excerpt] An Amgen Inc. drug increased the number ... and bleeding. Amgen has said that AMG 531 could have peak sales of $250 million. If you ... [/excerpt]
On Dec 8, 2004 in Los Angeles Times (subscription)

Patients Plead With Amgen for Parkinson's Drug
[excerpt] In June, its developer, Amgen, announced that the drug, which is called glial cell line- derived neurotrophic factor, or GDNF, had not proved better than a ... [/excerpt]
On Nov 29, 2004 in RedNova.com

Nominations Open for the Amgen Award For Science Teaching ...
[excerpt] Amgen Inc announced a call for nominations for its 14th annual Amgen Award for Science Teaching Excellence. This award is designed ... [/excerpt]
On Dec 4, 2004 in Onlypunjab.com (press release)

Baseball backers aid high school programs
[excerpt] Group is doing everything from giving high school baseball programs $3,000 grants to building professional-quality pitchers' mounds at the new Amgen field. ... [/excerpt]
On Dec 27, 2004 in Ventura County Star (subscription)

CEO Of The Year -- Medicine Man
[excerpt] In 2000 he became CEO of Amgen Inc., the world's largest and most well-known medical biotechnology company. ... Kevin Sharer was elected Amgen's CEO in May 2000. ... [/excerpt]
On Dec 22, 2004 in Industry Week

County's housing market experiences record prices
[excerpt] Amgen Inc. ... In November, the company committed $100 million to create Amgen Ventures as a vehicle to invest in emerging biotechnology companies. ... [/excerpt]
On Dec 27, 2004 in Ventura County Star (subscription)

Amgen CFO Nanula Elected to Boeing Board of Directors
[excerpt] Boeing has elected Richard D. Nanula, executive vice president and chief financial officer, Amgen Inc. to its board of directors effective January 1, 2005. ... [/excerpt]
On Dec 13, 2004 in ASIATravelTips.com

Amgen Announces $5 Billion Stock Repurchase Plan
[excerpt] Amgen Inc., the world's largest biotechnology company, today announced that its Board of Directors has authorized additional repurchases of up to $5 billion in ... [/excerpt]
On Dec 9, 2004 in Onlypunjab.com (press release)

Parkinson's patients denied drug they say really helps
[excerpt] But in late June, Amgen Inc., the developer and patent owner of the drug, announced that an early analysis of a larger, Phase II GDNF study, conducted at ... [/excerpt]
On Dec 20, 2004 in Kentucky.com

NPS Completes $175 Million Note Offering Backed by Sensipar(R) ...
[excerpt] The notes are secured by revenues paid to NPS from sales of Sensipar®, a drug licensed to and sold by Amgen Inc. for the treatment of hyperparathyroidism. ... [/excerpt]
On Dec 23, 2004 in Yahoo News (press release)

Burrill's Biotech Outlook for 2005 ...and a look back at 2004
[excerpt] Outcome: Big biotech M&A included: UCB/Celltech $2.7 billion Charles River/Inveresk $1.5 billion Amgen/Tularik $1.3 billion QLT/Atrix $750 million Invitrogen ... [/excerpt]
On Dec 22, 2004 in PR Newswire (press release)

Region's economy remained strong in 2004
[excerpt] ...stock value. Qualcomm even briefly rose past Amgen in value. It wasn't just Qualcomm. Small ... the county. Biotech giant Amgen Inc. of ... [/excerpt]
On Dec 25, 2004 in North County Times

Aranesp Every 2 Weeks Comparable to Epoetin Alfa Once a Week for ...
[excerpt] Amgen Inc today announced that data from a head-to-head study show that 200 mcg of Aranesp(R) (darbepoetin alfa) dosed once every two weeks has similar ... [/excerpt]
On Dec 13, 2004 in Onlypunjab.com (press release)

Scholars for dollars
[excerpt] In a complicated legal tussle, many biotech companies — including Amgen and Genentech, America’s two largest ones — had sued Columbia for seeking ... [/excerpt]
On Dec 23, 2004 in Economic Times

NPS places $175M in private notes
[excerpt] Announced during a Thursday teleconference, the notes - secured by royalties from Amgen Inc.'s sales of the NPS-developed hyperparathyroidism drug Sensipar ... [/excerpt]
On Dec 23, 2004 in Salt Lake Tribune

Anemia can make heart failure worse
[excerpt] Researchers at two hospitals and at Amgen, a company that makes drugs to treat anemia, looked at the role of anemia in chronic heart failure. ... [/excerpt]
On Dec 16, 2004 in U.S. News & World Report (subscription)

To: National Desk
[excerpt] Members of the committee have ties to some of the largest biotech and pharmaceutical companies in the world, including Pfizer and Amgen, which will look to ... [/excerpt]
On Dec 17, 2004 in U.S. Newswire (press release)

StockPickReport: Applied Materials Sell Rating
[excerpt] Inc., Broadcom Corporation, Amgen Inc. StockPickReport.Com ranks stocks with technical analysis. These ratings do not indicate a "long term" view. ... [/excerpt]
On Dec 23, 2004 in PrimeZone (press release)

Nine Picks In Biotech
[excerpt] The research firm said that while shares of "overweight"-rated Amgen (nasdaq: AMGN - news - people ) have had nice gains in the last two months, they still ... [/excerpt]
On Dec 20, 2004 in Forbes

Opinions Differ On What's Ahead In CMS Changes
[excerpt] ...dip in payments to clinics (as opposed to hospitals) giving the cancer drugs rightly has made investors edgy about the likes of biotechnology giants Amgen Inc. ... [/excerpt]
On Dec 17, 2004 in BioWorld Online (subscription)

Drug Treats Painful Side Effect of Chemotherapy
[excerpt] 16 (HealthDayNews) -- The US Food and Drug Administration has approved the Amgen intravenous drug Kepivance (palifermin) to prevent mucositis, a common side ... [/excerpt]
On Dec 16, 2004 in Atlanta Journal Constitution (subscription)

FDA Approves First Drug That Reduces Dangerous Treatment Side ...
[excerpt] Developed by Amgen, the drug palifermin (brand name Kepivance) was able to reduce by two-thirds the incidence of what can be a debilitating and life ... [/excerpt]
On Dec 16, 2004 in Cancerpage.com

Investors unsettled by drug news
[excerpt] ...of innovation. Biotechs have fared better. Amgen Inc. has risen to $64.15 from $57.99 on Sept. 29, while Genentech Inc. has been ... [/excerpt]
On Dec 24, 2004 in Indianapolis Star

Biotech companies stand to gain
[excerpt] Amgen Inc. ... For example, Michael Beckerich, spokesman for large biotech firm Amgen, says only two of the company's drugs are advertised on television. [/excerpt]
On Dec 24, 2004 in San Francisco Chronicle

Written Description - A Must Or Not
[excerpt] ...requirement. [xviii] In Amgen Inc. v. Hoechst Marion Roussel, the Federal Circuit noted that the written description requirement ... [/excerpt]
On Dec 21, 2004 in Mondaq News Alerts

Nominate teachers for science award
[excerpt] Biotechnology company Amgen Inc. is seeking nominations for its 14th Amgen Award for Science Teaching Excellence. This award is ... [/excerpt]
On Dec 8, 2004 in Kentucky.com

Phase 3 Study Shows Majority of Neutropenia with Related Fever and ...
[excerpt] Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today announced that new data from a Phase 3 study show that ... [/excerpt]
On Dec 10, 2004 in Business Wire (press release)

New Biotechnology Drug Approved to Treat Mucositis Associated with ...
[excerpt] ...or lymphoma. Palifermin will be marketed with the trade-name Kepivance and is manufactured by Amgen Inc., Thousand Oaks, Calif. [/excerpt]
On Dec 15, 2004 in FDA.gov

ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL
[excerpt] At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. ... [/excerpt]
On Dec 17, 2004 in ITNews

New Biotechnology Drug Approved to Treat Mucositis Associated with ...
[excerpt] ...lymphoma. Palifermin will be marketed with the trade-name Kepivance and is manufactured by Amgen Inc., Thousand Oaks, Calif. Palifermin ... [/excerpt]
On Dec 16, 2004 in PharmaLive.com (press release)

Volunteers help get field ready for first season
[excerpt] The only thing lacking Tuesday afternoon at the new Amgen baseball field in Thousand Oaks was turf to play on -- and that's why everyone was there. ... [/excerpt]
On Dec 16, 2004 in Ventura County Star (subscription)

Business briefs
[excerpt] The Food and Drug Administration has approved a new drug to fight severe mouth sores in certain cancer patients. California-based Amgen Inc. ... [/excerpt]
On Dec 16, 2004 in Denver Post

R&D Directions Magazine to Present 2005 Drug Development Summit
[excerpt] ATS, President, Research and Development US, sanofi-aventis; Dr. David R. Parkinson, Vice President Global Clinical Development, Oncology, Amgen, Inc.; Steven M ... [/excerpt]
On Dec 15, 2004 in PharmaLive.com (press release)

GAO Report Eases Biotech Fears
[excerpt] ...as Rituxan from Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ), and the anemia treatments made by Amgen (nasdaq: AMGN ... [/excerpt]
On Dec 2, 2004 in Forbes

StockPickReport: Buy Rating for Applied Materials
[excerpt] Materials, Merck & Co. Inc., Broadcom Corporation, Amgen Inc. Got some great questions recently. Here are our replies: 1. Exactly what ... [/excerpt]
On Dec 17, 2004 in PrimeZone (press release)

Eye On Stocks For Monday, Dec. 13
[excerpt] Biotech stalwart Amgen (nasdaq: AMGN - news - people ) announced favorable late-stage clinical data for Neulasta, a drug used to stave off infection in cancer ... [/excerpt]
On Dec 10, 2004 in Forbes

Some Biotech Stocks Are Bucking The Trend Says Dr. Joe Duarte
[excerpt] ...limbo, as their sister sector, the large pharmaceutical stocks, have been swooning behind Merck's (MRK) troubles, "three biotech stocks; Amgen (AMGN), Applera ... [/excerpt]
On Dec 1, 2004 in Investor's Business Daily (subscription)

Business Digest
[excerpt] ...quarters. Amgen Inc., the world's biggest biotechnology company, said it will buy back as much as $5 billion of its common stock. ... [/excerpt]
On Dec 7, 2004 in Seattle Post Intelligencer

Medarex Lifted By Pharmaceutical Alliances
[excerpt] MEDX - news - people ) and raised the target price after the company announced it will receive a milestone payment from licensing partner Amgen (nasdaq: AMGN ... [/excerpt]
On Nov 29, 2004 in Forbes

FDA Grants 'Fast-Track' Status to Drugs
[excerpt] Biotechnology company Amgen Inc. said Monday that the Food and Drug Administration granted a "fast-track" designation for two of ... [/excerpt]
On Dec 6, 2004 in Forbes

Buybacks Can Predict Profits
[excerpt] By Rich Duprey. Biotech behemoth Amgen (Nasdaq: AMGN) announced Tuesday that its board authorized a buyback of as much as $5 billion worth of stock. ... [/excerpt]
On Dec 8, 2004 in Motley Fool

Picking Biotech's Winners
[excerpt] We can't kid ourselves here, 99% of biotech companies do not have the treasure chest of an Amgen (Nasdaq: AMGN) or a Genentech (NYSE: DNA). ... [/excerpt]
On Nov 30, 2004 in Motley Fool

Business Digest
[excerpt] Richard Nanula, executive vice president and chief financial officer of Amgen Inc., has been elected to The Boeing Co.'s board of directors effective Jan. ... [/excerpt]
On Dec 14, 2004 in Seattle Post Intelligencer

The 10-Bagger You've Been Waiting For
[excerpt] ...where our children will work, not where our parents worked." This includes companies like biotech pioneer Amgen (Nasdaq: AMGN), DVD deliverer Netflix (Nasdaq ... [/excerpt]
On Dec 22, 2004 in Motley Fool

America's Best Big Companies
[excerpt] ...industry. More... By Robert Langreth. Amgen is on the verge of a renaissance that will target cancer, diabetes and more. These industry ... [/excerpt]
On Dec 23, 2004 in Forbes

Controversy embroils stem cell panel
[excerpt] For instance, Amgen, the world's largest biotech firm, lists among its board members Nobel Prize winner David Baltimore, the California Institute of Technology ... [/excerpt]
On Dec 17, 2004 in Sacramento Bee

Highlights of rising and falling US stocks
[excerpt] Amgen Inc. ... Dendreon (DNDN), AstraZeneca (AZN) and Amgen (AMGN) were among the drug developers to present results Saturday at a breast cancer symposium. ... [/excerpt]
On Dec 13, 2004 in Investor's Business Daily (subscription)

FDA Approves Kepivance™ for Treatment of Mucositis
[excerpt] Kepivance™. [1] Amgen. FDA ... Medicine . Available at: http://www.amgen.com/news/viewPR.jsp?id=655220. Accessed December 2004. [2 ... [/excerpt]
On Dec 16, 2004 in Cancer Consultants (press release)

Drug counterfeiters make big profits with little risk
[excerpt] Procrit, manufactured by Amgen and sold by a division of Johnson & Johnson (the company's best-selling drug, with $4 billion in sales) and used to treat ... [/excerpt]
On Dec 18, 2004 in Providence Journal (subscription)

Murphy in for a fight after 2 years at top
[excerpt] The deal that emerged had the company selling its corporate headquarters in West Greenwich to Amgen, then building a new headquarters in Providence and a new ... [/excerpt]
On Dec 13, 2004 in Providence Journal (subscription)

Mucositis, a Frequent Side Effect from Anticancer Therapy, Can Be ...
[excerpt] ...cancer patients are hospitalized. Palifermin is the first in a new class of drugs that was developed by Amgen Inc. Palifermin is the ... [/excerpt]
On Dec 15, 2004 in Business Wire (press release)

Israeli biotech: Too many kitchens, not enough chefs
[excerpt] ...merger between Pfizer and Esperion Therapeutics, the $879 million merger between Chiryon and Powerderject, the $1.3 billion merger between Amgen and Tularik ... [/excerpt]
On Dec 22, 2004 in Globes Online

Genetic Engineering News Lists Top Ten Biotechnology CEOs
[excerpt] GEN's top ten CEOs included Kevin Sharer, Amgen (AMGN:NASDAQ); Arthur D. Levinson, Ph.D., Genentech (DNA:NYSE); James C. Mullen, Biogen Idec (BIIB:NASDAQ ... [/excerpt]
On Dec 7, 2004 in Business Wire (press release)

Life Science Innovation Dependent on Venture Capital, New Report ...
[excerpt] Innovations Diabetes 18.2 million Therasense/Lifescan Blood Glucose Monitors Asthma 7 million Sepracor Xopenex Kidney Disease 300,000 Amgen EPOGEN Rheumatoid ... [/excerpt]
On Dec 1, 2004 in PR Newswire (press release)

Biogen Idec Shares Are 'Fully Priced'
[excerpt] On a valuation basis, the research firm considers Biogen Idec "fully priced" with aP/E-to-growth ratio of 1.6, compared with 1.0 for Amgen (nasdaq: AMGN - news ... [/excerpt]
On Dec 1, 2004 in Forbes

Drug warning: Remicade may cause lymphoma, a blood cancer
[excerpt] ...will be added to the drug's package insert and means the drug's safety profile will more closely match that of rival drugs in the same class, Amgen Inc.'s ... [/excerpt]
On Dec 4, 2004 in News Target

Johnson & Johnson Extends Talks on Guidant Purchase (Update1)
[excerpt] Sales of Procrit slid 12 percent in the third quarter to $887 million from $1 billion a year earlier because of competition from Amgen Inc.'s Aranesp. ... [/excerpt]
On Dec 13, 2004 in Bloomberg

US Stocks Decline in Europe; Johnson & Johnson Shares Fall
[excerpt] ...more than a decade. Amgen Inc., the world's biggest biotechnology company, climbed 44 cents to $63.98 in Germany. The company said ... [/excerpt]
On Dec 16, 2004 in Bloomberg

J&J's Big Buy
[excerpt] ...drugs could lose patent protection over the next few years, and top-seller Procrit, for anemia, is losing share to rival treatments from Amgen (nasdaq: AMGN ... [/excerpt]
On Dec 16, 2004 in Forbes,